New drug combo tested to fight tough stomach cancer
NCT ID NCT03223376
Summary
This study tested whether adding a drug called fruquintinib to standard paclitaxel chemotherapy works better than paclitaxel alone for people with advanced stomach cancer that worsened after initial treatment. It involved 703 participants and aimed to see if the combination helped people live longer or slowed cancer growth better, while checking for side effects. The trial was a Phase 3 study, meaning it was a large, late-stage test to gather strong evidence about the treatment's benefits and risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huchison Medi Pharma Investigational site
Nanjing, Jiangsu, 210000, China
-
Hutchison Medi Pharma Invesigational sites
Hefei, Anhui, 230000, China
-
Hutchison Medi Pharma Investigational Site
Guangzhou, Guangdong, 510030, China
-
Hutchison Medi Pharma Investigational site
Harbin, Heilongjiang, 150081, China
-
Hutchison Medi Pharma Investigational site
Shanghai, 200125, China
-
Hutchison Medi Pharma Investigational sites
Hangzhou, Zhejiang, 310000, China
-
Hutchison Medi Pharma Investigational sites
Beijing, 100142, China
Conditions
Explore the condition pages connected to this study.